Literature DB >> 15655364

c-Abl in oxidative stress, aging and cancer.

Baojie Li1.   

Abstract

c-Abl is activated by oxidative stress but its precise function in cell response to this stress is elusive. Studies of c-Abl(-/-) osteoblasts revealed that c-Abl played a negative role in the induction of peroxiredoxin I (Prx I, Prdx I), an anti-oxidant protein with tumor suppression activity. In contrast, Atm, a signaling molecule that interacts with c-Abl and is required for c-Abl activation, served a totally different function. The significance of these findings is discussed here in the context of aging and tumorigenesis and their links to reactive oxygen species. c-Abl and its derivatives BCR-ABL and v-Abl were discovered more than twenty years ago. BCR-ABL and v-Abl acquire elevated tyrosine kinase activities by fusing to BCR and gag respectively and are capable of transforming myeloid and fibroblast cells. BCR-ABL is also the underlying cause in the development of most cases of chronic myeloid leukemia (CML) in humans. In contrast, c-Abl takes on an auto-inhibiting conformation and its activation requires post-translational modifications such as phosphorylation and myristoylation. The physiological functions of c-Abl remain elusive.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15655364

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  10 in total

1.  Minimal peroxide exposure of neuronal cells induces multifaceted adaptive responses.

Authors:  Wayne Chadwick; Yu Zhou; Sung-Soo Park; Liyun Wang; Nicholas Mitchell; Matthew D Stone; Kevin G Becker; Bronwen Martin; Stuart Maudsley
Journal:  PLoS One       Date:  2010-12-17       Impact factor: 3.240

2.  Involvement of c-Abl, p53 and the MAP kinase JNK in the cell death program initiated in A2E-laden ARPE-19 cells by exposure to blue light.

Authors:  Barbro S Westlund; Bolin Cai; Jilin Zhou; Janet R Sparrow
Journal:  Apoptosis       Date:  2009-01       Impact factor: 4.677

Review 3.  Multifunctional Abl kinases in health and disease.

Authors:  Aaditya Khatri; Jun Wang; Ann Marie Pendergast
Journal:  J Cell Sci       Date:  2016-01-01       Impact factor: 5.285

Review 4.  Mdm2 links genotoxic stress and metabolism to p53.

Authors:  Zhongfeng Wang; Baojie Li
Journal:  Protein Cell       Date:  2011-01-08       Impact factor: 14.870

5.  Accelerated Discovery of Novel Ponatinib Analogs with Improved Properties for the Treatment of Parkinson's Disease.

Authors:  Thomas M Kaiser; Zackery W Dentmon; Christopher E Dalloul; Savita K Sharma; Dennis C Liotta
Journal:  ACS Med Chem Lett       Date:  2020-03-12       Impact factor: 4.345

6.  A role for c-Abl in cell senescence and spontaneous immortalization.

Authors:  Man Zhang; Lili Li; Zhongfeng Wang; Huijuan Liu; Junlin Hou; Min Zhang; Aijun Hao; Yun Liu; Guang He; Yongyong Shi; Lin He; Xueying Wang; Yue Wan; Baojie Li
Journal:  Age (Dordr)       Date:  2012-07-13

7.  The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease.

Authors:  Senthilkumar S Karuppagounder; Saurav Brahmachari; Yunjong Lee; Valina L Dawson; Ted M Dawson; Han Seok Ko
Journal:  Sci Rep       Date:  2014-05-02       Impact factor: 4.379

8.  c-Abl regulates gastrointestinal muscularis propria homeostasis via ERKs.

Authors:  Jinnan Xiang; Yiqun Zhang; Dandan Bao; Na Cao; Xin Zhang; Ping Li; Shoutao Qiu; Jigang Guo; Dan He; Baojie Li; Liqing Yao; Huijuan Liu
Journal:  Sci Rep       Date:  2017-06-15       Impact factor: 4.379

9.  Genetic studies of bone diseases: evidence for involvement of DNA damage response proteins in bone remodeling.

Authors:  Xueying Wang; Baojie Li
Journal:  Int J Biomed Sci       Date:  2007-12

10.  The c-Abl inhibitor, Radotinib HCl, is neuroprotective in a preclinical Parkinson's disease mouse model.

Authors:  Saebom Lee; Sangjune Kim; Yong Joo Park; Seung Pil Yun; Seung-Hwan Kwon; Donghoon Kim; Dong Yeon Kim; Jae Soo Shin; Dae Jin Cho; Gong Yeal Lee; Hyun Soo Ju; Hyo Jung Yun; Jae Hong Park; Wonjoong Richard Kim; Eun Ah Jung; Seulki Lee; Han Seok Ko
Journal:  Hum Mol Genet       Date:  2018-07-01       Impact factor: 6.150

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.